

Florence Pasquier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2337453/publications.pdf>

Version: 2024-02-01

409
papers

53,968
citations

3933

88
h-index

1536

218
g-index

451
all docs

451
docs citations

451
times ranked

41137
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Scale to Assess Caregiver Management Behaviors in Response to the Decreased Engagement of People with Dementia in Daily Activities. <i>Clinical Gerontologist</i> , 2022, 45, 514-524.	2.2	2
2	The Clinical Value of the Faux Pas Test for Diagnosing Behavioral-Variant Frontotemporal Dementia. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 62-65.	2.3	5
3	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 158-168.	1.9	7
4	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
5	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
6	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
7	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
8	The <sc>CBIâ€R</sc> detects early behavioural impairment in genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 644-658.	3.7	1
9	Telemedicine in French Memory Clinics During the COVID-19 Pandemic. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 525-530.	2.6	3
10	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
11	Interoception and social cognition in chronic low back pain: a common inference disturbance? An exploratory study. <i>Pain Management</i> , 2022, 12, 471-485.	1.5	3
12	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. <i>Neurology</i> , 2022, 99, .	1.1	5
13	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 652.	9.0	31
14	A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. <i>Neurology</i> , 2022, 99, .	1.1	8
15	Does culture shape our understanding of othersâ€™ thoughts and emotions? An investigation across 12 countries.. <i>Neuropsychology</i> , 2022, 36, 664-682.	1.3	19
16	Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	14
17	Plasma microRNA signature in presymptomatic and symptomatic subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 485-493.	1.9	25
18	Clinical relevance of brain atrophy subtypes categorization in memory clinics. <i>Alzheimer's and Dementia</i> , 2021, 17, 641-652.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	2.4	11
20	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
21	Investigating the association between cancer and the risk of dementia: Results from the Memento cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1415-1421.	0.8	12
22	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. <i>Biological Psychiatry</i> , 2021, 89, 825-835.	1.3	10
23	Primary Progressive Aphasia Associated With <i>GRN</i> Mutations. <i>Neurology</i> , 2021, 97, e88-e102.	1.1	23
24	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
25	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	30.7	182
26	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
27	Diabetes Mellitus and Cognition. <i>Neurology</i> , 2021, 97, e836-e848.	1.1	23
28	Plasma NFL levels and longitudinal change rates in <i>C9orf72</i> and <i>GRN</i> -associated diseases: from tailored references to clinical applications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1278-1288.	1.9	25
29	A multimodal, longitudinal study of cognitive heterogeneity in early-onset Alzheimer's disease. <i>European Journal of Neurology</i> , 2021, 28, 3990-3998.	3.3	3
30	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. <i>Neurobiology of Aging</i> , 2021, 108, 155-167.	3.1	3
31	Primary progressive aphasia associated with <i>C9orf72</i> expansions: Another side of the story. <i>Cortex</i> , 2021, 145, 145-159.	2.4	9
32	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
33	Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 19.	6.2	25
34	<i>SLITRK2</i> , an X-linked modifier of the age at onset in <i>C9orf72</i> frontotemporal lobar degeneration. <i>Brain</i> , 2021, 144, 2798-2811.	7.6	7
35	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 1439-1446.	2.6	2
36	Longitudinal Analysis of Brain-Predicted Age in Amnesic and Non-amnesic Sporadic Early-Onset Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 729635.	3.4	7

#	ARTICLE	IF	CITATIONS
37	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
38	An acceptance, role transition, and couple dynamics-based program for caregivers: A qualitative study of the experience of spouses of persons with young-onset dementia. <i>Dementia</i> , 2020, 19, 2714-2731.	2.0	16
39	Differences in cortical perfusion detected by arterial spin labeling in nonamnesic and amnesic subtypes of early-onset Alzheimer's disease. <i>Journal of Neuroradiology</i> , 2020, 47, 284-291.	1.1	5
40	Sex Differences in the Occurrence of Major Clinical Events in Elderly People with Type 2 Diabetes Mellitus Followed up in the General Practice. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2020, 128, 311-318.	1.2	4
41	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 194-200.	2.5	21
42	Three-year changes of cortical 18F-FDG in amnesic vs. non-amnesic sporadic early-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 304-318.	6.4	4
43	Antihypertensive agents in Alzheimer's disease: beyond vascular protection. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 175-187.	2.8	26
44	Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. <i>Neurobiology of Aging</i> , 2020, 95, 123-130.	3.1	15
45	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020, 10, 12184.	3.3	4
46	Visit-to-Visit Blood Pressure Variability Is Associated With Cognitive Decline and Incident Dementia. <i>Hypertension</i> , 2020, 76, 1280-1288.	2.7	57
47	Subjective cognitive and non-cognitive complaints and brain MRI biomarkers in the MEMENTO cohort. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12051.	2.4	7
48	Twenty-year trends in patient referrals throughout the creation and development of a regional memory clinic network. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12048.	3.7	7
49	Sedative Load in Community-Dwelling Older Adults with Mild to Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. <i>Drugs and Aging</i> , 2020, 37, 829-837.	2.7	5
50	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. <i>Frontiers in Neurology</i> , 2020, 11, 149.	2.4	14
51	Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience. <i>Neurobiology of Aging</i> , 2020, 91, 167.e1-167.e9.	3.1	24
52	Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. <i>Brain</i> , 2020, 143, 1632-1650.	7.6	158
53	Cognitive inhibition impairments in presymptomatic <i>C9orf72</i> carriers. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 366-372.	1.9	14
54	Post-Mortem 7.0-Tesla Magnetic Resonance Imaging of the Hippocampus in Progressive Supranuclear Palsy with and without Cerebral Amyloid Angiopathy. <i>NeuroSci</i> , 2020, 1, 115-120.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 227-243.	2.6	39
56	Using EQ-PET to reduce reconstruction-dependent variations in [18F]FDG-PET brain imaging. <i>Physics in Medicine and Biology</i> , 2019, 64, 175002.	3.0	2
57	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	1.9	16
58	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. <i>BMJ Open</i> , 2019, 9, e026380.	1.9	17
59	Blood Pressure Lowering With Nilvadipine in Patients With Mild-to-Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. <i>Journal of the American Heart Association</i> , 2019, 8, e011938.	3.7	10
60	Frontotemporal dementia is the leading cause of $\Delta A\beta/T+$ profiles defined with $\Delta A\beta_{42/40}$ ratio. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 161-169.	2.4	8
61	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates $A\beta$, tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
62	The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 324-333.	6.4	6
63	Neurite density is reduced in the presymptomatic phase of <i>C9orf72</i> disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 387-394.	1.9	50
64	Role of cortical microbleeds in cognitive impairment: In vivo behavioral and imaging characterization of a novel murine model. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 1015-1025.	4.3	9
65	A Customized Intervention for Dementia Caregivers: A Quasi-Experimental Design. <i>Journal of Aging and Health</i> , 2019, 31, 1172-1195.	1.7	12
66	Cerebral microbleeds and CSF Alzheimer biomarkers in primary progressive aphasia. <i>Neurology</i> , 2018, 90, e1057-e1065.	1.1	13
67	Early Cognitive, Structural, and Microstructural Changes in Presymptomatic <i>C9orf72</i> Carriers Younger Than 40 Years. <i>JAMA Neurology</i> , 2018, 75, 236.	9.0	108
68	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , 2018, 17, 548-558.	10.2	97
69	Hyperinsulinemic hypoglycemia without insulinoma: Think of activating glucokinase mutation. <i>Presse Medicale</i> , 2018, 47, 595-597.	1.9	4
70	Characteristics of the spouse caregiving experience: Comparison between early- and late-onset dementia. <i>Aging and Mental Health</i> , 2018, 22, 1213-1221.	2.8	10
71	Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2018, 14, 280-292.	0.8	246
72	First principle study on the electronic properties and Schottky contact of graphene adsorbed on MoS ₂ monolayer under applied out-plane strain. <i>Surface Science</i> , 2018, 668, 23-28.	1.9	39

#	ARTICLE	IF	CITATIONS
73	Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study. <i>Canadian Journal of Diabetes</i> , 2018, 42, 365-371.e2.	0.8	7
74	Added value of ¹⁸ F-florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. <i>Alzheimer's and Dementia</i> , 2018, 14, 293-305.	0.8	48
75	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018, 141, 2895-2907.	7.6	39
76	Prevalence of amyloid β pathology in distinct variants of primary progressive aphasia. <i>Annals of Neurology</i> , 2018, 84, 729-740.	5.3	132
77	Structural, Microstructural, and Metabolic Alterations in Primary Progressive Aphasia Variants. <i>Frontiers in Neurology</i> , 2018, 9, 766.	2.4	33
78	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. <i>PLoS Medicine</i> , 2018, 15, e1002660.	8.4	131
79	Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides A β 1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 297.	3.4	10
80	Neural correlates of episodic memory in the Memento cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 224-233.	3.7	23
81	Influence of Lewy Pathology on Alzheimer's Disease Phenotype: A Retrospective Clinico-Pathological Study. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1317-1323.	2.6	18
82	Attentional capture by incongruent object/background scenes in patients with Alzheimer disease. <i>Cortex</i> , 2018, 107, 4-12.	2.4	9
83	Ageing and cerebrovascular lesions in pure and in mixed neurodegenerative and vascular dementia brains: a neuropathological study. <i>Folia Neuropathologica</i> , 2018, 56, 81-87.	1.2	67
84	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. <i>Current Alzheimer Research</i> , 2018, 15, 691-700.	1.4	5
85	Do spouse caregivers of persons with early- and late-onset dementia cope differently? A comparative study. <i>Archives of Gerontology and Geriatrics</i> , 2017, 69, 162-168.	3.0	19
86	Do spouse caregivers of young and older persons with dementia have different needs? A comparative study. <i>Psychogeriatrics</i> , 2017, 17, 282-291.	1.2	31
87	Cerebrovascular Lesions in Mixed Neurodegenerative Dementia: A Neuropathological and Magnetic Resonance Study. <i>European Neurology</i> , 2017, 78, 1-5.	1.4	9
88	The Vascular Impairment of Cognition Classification Consensus Study. <i>Alzheimer's and Dementia</i> , 2017, 13, 624-633.	0.8	143
89	17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression. <i>Molecular Psychiatry</i> , 2017, 22, 1119-1125.	7.9	57
90	Topographic distribution of brain iron deposition and small cerebrovascular lesions in amyotrophic lateral sclerosis and in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance imaging study with neuropathological correlates. <i>Acta Neurologica Belgica</i> , 2017, 117, 873-878.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Update on tauopathies. <i>Current Opinion in Neurology</i> , 2017, 30, 589-598.	3.6	54
92	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
93	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. <i>Neurobiology of Aging</i> , 2017, 59, 220.e1-220.e9.	3.1	116
94	18F-FDG PET hypometabolism patterns reflect clinical heterogeneity in sporadic forms of early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 59, 184-196.	3.1	27
95	[P3â€“364]: ACCELERATED SUBCORTICAL ATROPHY DURING AGING IN PRESYMPTOMATIC CARRIERS OF C9ORF72 MUTATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P1096.	0.8	0
96	[ICâ€“Pâ€“126]: ACCELERATED SUBCORTICAL ATROPHY DURING AGING IN PRESYMPTOMATIC CARRIERS OF C9ORF72 MUTATION. <i>Alzheimer's and Dementia</i> , 2017, 13, P95.	0.8	0
97	Frontotemporal Dementia. <i>Neuropsychiatric Symptoms of Neurological Disease</i> , 2017, , 279-302.	0.3	0
98	Relationship between achieved personalized glycaemic targets and monitoring of clinical events in elderly diabetic patients. <i>Diabetes and Metabolism</i> , 2017, 43, 59-68.	2.9	1
99	[P1â€“240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. <i>Alzheimer's and Dementia</i> , 2017, 13, P336.	0.8	1
100	[P4â€“251]: PATTERNS OF CORTICAL NEUROANATOMICAL ABNORMALITIES IN TYPICAL AND ATYPICAL SPORADIC FORMS OF EARLYâ€“ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1375.	0.8	0
101	[ICâ€“Pâ€“107]: PATTERNS OF CORTICAL NEUROANATOMICAL ABNORMALITIES IN TYPICAL AND ATYPICAL SPORADIC FORMS OF EARLYâ€“ONSET ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P82.	0.8	0
102	[P1â€“251]: CLINICAL PROFILE OF PATIENTS WITH NORMAL CSF AÎ²42 AND AÎ²42/AÎ²40 RATIO, YET ABNORMAL CSF 181Pâ€“TAU: A SNAP STORY. <i>Alzheimer's and Dementia</i> , 2017, 13, P343.	0.8	1
103	Factors influencing the age at onset in familial frontotemporal lobar dementia. <i>Neurology: Genetics</i> , 2017, 3, e203.	1.9	8
104	Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 67.	6.2	45
105	Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1045-1054.	2.6	22
106	Frequency and topography of small cerebrovascular lesions in vascular and in mixed dementia: a post-mortem 7-tesla magnetic resonance imaging study with neuropathological correlates. <i>Folia Neuropathologica</i> , 2017, 1, 31-37.	1.2	8
107	APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. <i>PLoS Medicine</i> , 2017, 14, e1002270.	8.4	358
108	AÎ²1-40 and AÎ²1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#. <i>Current Alzheimer Research</i> , 2017, 14, 686-694.	1.4	11

#	ARTICLE	IF	CITATIONS
109	Young onset demented patients in French cognitive-behavioral specialized units. <i>Psychologie & Neuropsychiatrie Du Vieillessement</i> , 2016, 14, 194-200.	0.2	3
110	Cerebral Hypoperfusion and Hypometabolism Detected by Arterial Spin Labeling MRI and FDG-PET in Early-Onset Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2016, 26, 207-212.	2.0	73
111	Modeling the Distress of Spousal Caregivers of People with Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 703-716.	2.6	24
112	Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 905-913.	2.6	21
113	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1459-1471.	2.6	28
114	Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial. <i>International Psychogeriatrics</i> , 2016, 28, 707-717.	1.0	96
115	Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridifcar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 1131-1143.	2.6	78
116	Qualitative and quantitative assessment of self-reported cognitive difficulties in nondemented elders: Association with medical help seeking, cognitive deficits, and 125 I-amyloid imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 23-34.	2.4	47
117	P1-291: Hypometabolism Patterns Using FDG-PET in Typical and Atypical Sporadic Forms of Early-Onset Alzheimer's Disease. , 2016, 12, P532-P532.		3
118	ICP-149: Qualitative Assessment of Self-Reported Cognitive Difficulties in Non-Demented Elders: Relationships With Medical Help Seeking, Cognition and Neuroimaging Biomarkers. <i>Alzheimer's and Dementia</i> , 2016, 12, P110.	0.8	0
119	P1-394: Prevalence and Characteristics of Patients with Alzheimer's Disease Eligible for a Disease Modifying Drug (Panacea). , 2016, 12, P584-P584.		0
120	ICP-113: Hypometabolism Patterns Using FDG-PET in Typical and Atypical Sporadic Forms of Early-Onset Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P85.	0.8	0
121	P2-343: Qualitative Assessment of Self-Reported Cognitive Difficulties in Non-Demented Elders: Relationships with Medical Help Seeking, Cognition and Neuroimaging Biomarkers. <i>Alzheimer's and Dementia</i> , 2016, 12, P774.	0.8	0
122	P1-058: Nilvad: An Investigator Driven Phase III Multi Centre European Clinical Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P424.	0.8	0
123	The incidence of post-mortem neurodegenerative and cerebrovascular pathology in mixed dementia. <i>Journal of the Neurological Sciences</i> , 2016, 366, 164-166.	0.6	32
124	Mosaic Loss of Chromosome Y in Blood Is Associated with Alzheimer Disease. <i>American Journal of Human Genetics</i> , 2016, 98, 1208-1219.	6.2	164
125	<i>ABCA7</i> rare variants and Alzheimer disease risk. <i>Neurology</i> , 2016, 86, 2134-2137.	1.1	63
126	Cognition and neuropsychiatry in behavioral variant frontotemporal dementia by disease stage. <i>Neurology</i> , 2016, 87, 1523-1523.	1.1	1

#	ARTICLE	IF	CITATIONS
127	Lobar intracerebral haematomas: Neuropathological and 7.0-tesla magnetic resonance imaging evaluation. <i>Journal of the Neurological Sciences</i> , 2016, 369, 121-125.	0.6	1
128	Seizures in dominantly inherited Alzheimer disease. <i>Neurology</i> , 2016, 87, 912-919.	1.1	81
129	Shared genetic contribution to ischemic stroke and Alzheimer's disease. <i>Annals of Neurology</i> , 2016, 79, 739-747.	5.3	56
130	The Topography of Cortical Microinfarcts in Neurodegenerative Diseases and in Vascular Dementia: A Postmortem 7.0-Tesla Magnetic Resonance Imaging Study. <i>European Neurology</i> , 2016, 76, 57-61.	1.4	11
131	The <i>MAPT</i> gene is differentially methylated in the progressive supranuclear palsy brain. <i>Movement Disorders</i> , 2016, 31, 1883-1890.	3.9	25
132	P305: Exploring the Anatomical Substrate of Episodic Memory: the Structural Mri Correlates of the Free and Cued Selective Reminding Test in the Memento Cohort. <i>Alzheimer's and Dementia</i> , 2016, 12, P958.	0.8	0
133	Coordinating Supply Chains With a General Price-Dependent Demand Function: Impacts of Channel Leadership and Information Asymmetry. <i>IEEE Transactions on Engineering Management</i> , 2016, 63, 390-403.	3.5	32
134	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 27.	6.2	18
135	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease—the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. <i>BMJ Open</i> , 2016, 6, e011584.	1.9	21
136	Cardiovascular Drugs and Metformin Drug Dosage According to Renal Function in Noninstitutionalized Elderly Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 468-473.	2.5	7
137	Topographic distribution of white matter changes and lacunar infarcts in neurodegenerative and vascular dementia syndromes: A post-mortem 7.0-tesla magnetic resonance imaging study. <i>European Stroke Journal</i> , 2016, 1, 122-129.	5.5	9
138	ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer's Disease. <i>EBioMedicine</i> , 2016, 9, 278-292.	6.1	40
139	Multiple Simultaneous Spontaneous Intracerebral Hemorrhages: A Rare Entity. <i>Cerebrovascular Diseases</i> , 2016, 41, 74-79.	1.7	18
140	Couples' experiences with early-onset dementia: An interpretative phenomenological analysis of dyadic dynamics. <i>Dementia</i> , 2016, 15, 1082-1099.	2.0	68
141	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. <i>Alzheimer's and Dementia</i> , 2016, 12, 614-622.	0.8	42
142	Apolipoprotein E (APOE) ϵ 4 and episodic memory decline in Alzheimer's disease: A review. <i>Ageing Research Reviews</i> , 2016, 27, 15-22.	10.9	70
143	A Comparative Descriptive Study of Characteristics of Early- and Late-Onset Dementia Family Caregivers. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 48-56.	1.9	33
144	From "needing to know" to "needing not to know more": an interpretative phenomenological analysis of couples' experiences with early-onset Alzheimer's disease. <i>Scandinavian Journal of Caring Sciences</i> , 2016, 30, 695-703.	2.1	27

#	ARTICLE	IF	CITATIONS
145	Screening of dementia genes by whole-exome sequencing in early-onset Alzheimer disease: input and lessons. <i>European Journal of Human Genetics</i> , 2016, 24, 710-716.	2.8	77
146	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. <i>Molecular Psychiatry</i> , 2016, 21, 831-836.	7.9	96
147	A novel Alzheimer disease locus located near the gene encoding tau protein. <i>Molecular Psychiatry</i> , 2016, 21, 108-117.	7.9	260
148	Reduced Regional Cortical Thickness Rate of Change in Donepezil-Treated Subjects With Suspected Prodromal Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1631-e1638.	2.2	38
149	The topography of cortical microbleeds in frontotemporal lobar degeneration: a post-mortem 7.0-tesla magnetic resonance study. <i>Folia Neuropathologica</i> , 2016, 2, 149-155.	1.2	3
150	DAPHNE: A New Tool for the Assessment of the Behavioral Variant of Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 503-516.	1.3	31
151	Analysing time to event data in dementia prevention trials: The example of the guidance study of EGB761A®. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 1009-1011.	3.3	13
152	Cerebrospinal fluid amyloid- β 42/40 ratio in clinical setting of memory centers: a multicentric study. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 30.	6.2	101
153	Lateral Temporal Lobe: An Early Imaging Marker of the Presymptomatic GRN Disease?. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 751-759.	2.6	34
154	Association between Cardiovascular Drugs and Chronic Kidney Disease in Non-Institutionalized Elderly Patients. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 117, 137-143.	2.5	5
155	Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 1075-1083.	2.6	3
156	Primary care management of non-institutionalized elderly diabetic patients: The S.AGES cohort "Baseline data. <i>Primary Care Diabetes</i> , 2015, 9, 267-274.	1.8	9
157	Detection of Cortical Microbleeds in Postmortem Brains of Patients with Lewy Body Dementia: A 7.0-Tesla Magnetic Resonance Imaging Study with Neuropathological Correlates. <i>European Neurology</i> , 2015, 74, 158-161.	1.4	11
158	Scene Categorization in Alzheimer's Disease: A Saccadic Choice Task. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 1-12.	1.3	15
159	Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 1041-1049.	0.8	102
160	Predicting falls in elderly patients with chronic pain and other chronic conditions. <i>Aging Clinical and Experimental Research</i> , 2015, 27, 653-661.	2.9	13
161	Sociolinguistic reflection on neuropsychological assessment: an insight into selected culturally adapted battery of Lebanese Arabic cognitive testing. <i>Neurological Sciences</i> , 2015, 36, 1813-1822.	1.9	9
162	PLD3 and sporadic Alzheimer's disease risk. <i>Nature</i> , 2015, 520, E1-E1.	27.8	54

#	ARTICLE	IF	CITATIONS
163	Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 219-227.	3.3	7
164	The Significance of Cortical Cerebellar Microbleeds and Microinfarcts in Neurodegenerative and Cerebrovascular Diseases. <i>Cerebrovascular Diseases</i> , 2015, 39, 138-143.	1.7	42
165	Survival and early recourse to care for dementia: A population based study. <i>Alzheimer's and Dementia</i> , 2015, 11, 385-393.	0.8	19
166	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 17.	6.2	419
167	Optimization of brain perfusion image quality by cortical surface-based projection of arterial spin labeling maps in early-onset Alzheimer's disease patients. <i>European Radiology</i> , 2015, 25, 2479-2484.	4.5	7
168	Healthcare costs associated with elderly chronic pain patients in primary care. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 939-947.	1.9	11
169	TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. <i>Neurobiology of Aging</i> , 2015, 36, 3116.e5-3116.e8.	3.1	63
170	A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormone therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 569-580.	2.5	32
171	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 658-671.	0.8	173
172	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.8	56
173	Topography of Cortical Microbleeds in Alzheimer's Disease with and without Cerebral Amyloid Angiopathy: A Post-Mortem 7.0-Tesla MRI Study. , 2015, 6, 437.		16
174	Differential processing of natural scenes in posterior cortical atrophy and in Alzheimer's disease, as measured with a saccade choice task. <i>Frontiers in Integrative Neuroscience</i> , 2014, 8, 60.	2.1	17
175	Original article Prevalence of small cerebral bleeds in patients with progressive supranuclear palsy: a neuropathological study with 7.0-Tesla magnetic resonance imaging correlates. <i>Folia Neuropathologica</i> , 2014, 4, 421-427.	1.2	6
176	Validation of the Test Your Memory (F-TYM Test) in a French Memory Clinic Population. <i>Clinical Neuropsychologist</i> , 2014, 28, 994-1007.	2.3	10
177	Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1405-1408.	1.9	120
178	Iron deposits in post-mortem brains of patients with neurodegenerative and cerebrovascular diseases: a semi-quantitative 7.0-T magnetic resonance imaging study. <i>European Journal of Neurology</i> , 2014, 21, 1026-1031.	3.3	53
179	Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 1237-1242.	1.9	12
180	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 38.	6.2	44

#	ARTICLE	IF	CITATIONS
181	Unmet support needs of early-onset dementia family caregivers: a mixed-design study. BMC Nursing, 2014, 13, 49.	2.5	53
182	Diagnostic Criteria for Vascular Cognitive Disorders. Alzheimer Disease and Associated Disorders, 2014, 28, 206-218.	1.3	529
183	Impact of harmonization of collection tubes on Alzheimer's disease diagnosis. , 2014, 10, S390-S394.e2.		58
184	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	3.6	56
185	Unusual features of Creutzfeldt-Jakob disease followed-up in a memory clinic. Journal of Neurology, 2014, 261, 696-701.	3.6	9
186	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
187	Cerebral amyloid angiopathy revealed by rapidly progressing leptomeningeal lesions. Journal of Neurology, 2014, 261, 1432-1435.	3.6	1
188	Influence of cognitive impairment on the management of ischaemic stroke. Revue Neurologique, 2014, 170, 177-186.	1.5	4
189	Post-mortem 7.0-tesla magnetic resonance study of cortical microinfarcts in neurodegenerative diseases and vascular dementia with neuropathological correlates. Journal of the Neurological Sciences, 2014, 346, 85-89.	0.6	46
190	Who Needs Cerebrospinal Biomarkers? A National Survey in Clinical Practice. Journal of Alzheimer's Disease, 2014, 40, 857-861.	2.6	22
191	Contribution of <i>ATXN2</i> intermediary polyQ expansions in a spectrum of neurodegenerative disorders. Neurology, 2014, 83, 990-995.	1.1	70
192	Effects of the PPAR- α Agonist Fenofibrate on Acute and Short-Term Consequences of Brain Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 542-551.	4.3	51
193	Neuronal substrate of cognitive impairment in post-stroke dementia. Brain, 2014, 137, 2404-2405.	7.6	5
194	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
195	Thrombolytic therapy for stroke in patients with preexisting cognitive impairment. Neurology, 2014, 82, 2048-2054.	1.1	20
196	Animal Spotting in Alzheimer's Disease: An Eye Tracking Study of Object Categorization. Journal of Alzheimer's Disease, 2014, 39, 181-189.	2.6	19
197	P3-277: DO GERIATRIC AND NEUROLOGICAL MEMORY CLINICS DIFFER? A LONGITUDINAL STUDY OVER 16 YEARS OF A NETWORK OF MEMORY CLINICS IN FRANCE. , 2014, 10, P733-P733.		0
198	THE ROLE OF THE MEMORY RESOURCES AND RESEARCH CENTER IS ENHANCED BY A 16-YEAR NETWORK ORGANIZATION OF MEMORY CLINICS IN THE NORTH OF FRANCE. , 2014, 10, P223-P223.		0

#	ARTICLE	IF	CITATIONS
199	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. <i>BMJ Open</i> , 2014, 4, e006364.	1.9	47
200	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e94661.	2.5	155
201	Caring for Individuals with Early-Onset Dementia and Their Family Caregivers: The Perspective of Health Care Professionals. <i>Advances in Alzheimer's Disease</i> , 2014, 03, 33-43.	0.9	13
202	Prevalence of cerebrovascular lesions in patients with Lewy body dementia: A neuropathological study. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1094-1097.	1.4	28
203	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	21.4	3,741
204	Superficial Siderosis of the Central Nervous System: A Post-Mortem 7.0-Tesla Magnetic Resonance Imaging Study with Neuropathological Correlates. <i>Cerebrovascular Diseases</i> , 2013, 36, 412-417.	1.7	26
205	Exacerbated CSF abnormalities in younger patients with Alzheimer's disease. <i>Neurobiology of Disease</i> , 2013, 54, 486-491.	4.4	14
206	Memory loss during lenalidomide treatment: a report on two cases. <i>BMC Pharmacology & Toxicology</i> , 2013, 14, 41.	2.4	19
207	New behavioural variant FTD criteria and clinical practice. <i>Revue Neurologique</i> , 2013, 169, 799-805.	1.5	6
208	Action and noun fluency testing to distinguish between Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2013, 35, 259-268.	1.3	22
209	C9ORF72 Repeat Expansions in the Frontotemporal Dementias Spectrum of Diseases: A Flow-chart for Genetic Testing. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 485-499.	2.6	93
210	C9orf72 repeat expansions are a rare genetic cause of parkinsonism. <i>Brain</i> , 2013, 136, 385-391.	7.6	143
211	Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. <i>Alzheimer's and Dementia</i> , 2013, 9, 406-413.	0.8	63
212	Adenosine Receptors and Alzheimer's Disease. , 2013, , 385-407.		2
213	Emotional and Psychological Implications of Early AD Diagnosis. <i>Medical Clinics of North America</i> , 2013, 97, 459-475.	2.5	26
214	The Unique Experience of Spouses in Early-Onset Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 634-641.	1.9	98
215	Microbleeds in Postmortem Brains of Patients With Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 162-167.	1.3	19
216	Reasons that prevent the inclusion of Alzheimer's disease patients in clinical trials. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1089-1097.	2.4	24

#	ARTICLE	IF	CITATIONS
217	Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. <i>Molecular Psychiatry</i> , 2013, 18, 461-470.	7.9	103
218	Does pre-existing cognitive impairment no-dementia influence the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia?: Table A1. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1412-1414.	1.9	18
219	Impact of the 2008-2012 French Alzheimer Plan on the Use of Cerebrospinal Fluid Biomarkers in Research Memory Center: The PLM Study. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 297-305.	2.6	51
220	National Observatory on the Therapeutic Management in Ambulatory Care Patients Aged 65 and Over, with Type 2 Diabetes, Chronic Pain or Atrial Fibrillation. <i>Therapie</i> , 2013, 68, 265-283.	1.0	17
221	A New Decision Tree Combining Abeta 1-42 and p-Tau Levels in Alzheimer's Diagnosis. <i>Current Alzheimer Research</i> , 2013, 10, 357-364.	1.4	19
222	My belief or yours? Differential theory of mind deficits in frontotemporal dementia and Alzheimer's disease. <i>Brain</i> , 2012, 135, 3026-3038.	7.6	114
223	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. <i>Current Alzheimer Research</i> , 2012, 9, 902-912.	1.4	42
224	<sc>EFNS</sc> Guidelines on the diagnosis and management of disorders associated with dementia. <i>European Journal of Neurology</i> , 2012, 19, 1159-1179.	3.3	239
225	Can the Treatment of Vascular Risk Factors Slow Cognitive Decline in Alzheimer's Disease Patients?. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 765-772.	2.6	19
226	The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 847-856.	2.6	113
227	Definite Behavioral Variant of Frontotemporal Dementia with C9ORF72 Expansions Despite Positive Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 19-22.	2.6	32
228	Steroid and nonsteroidal anti-inflammatory drugs, cognitive decline, and dementia. <i>Neurobiology of Aging</i> , 2012, 33, 2082-2090.	3.1	27
229	Insulin-Like Growth Factor-I and Insulin-Like Growth Factor Binding Protein-3 in Alzheimer's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 4673-4681.	3.6	63
230	Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. <i>Molecular Neurodegeneration</i> , 2012, 7, 3.	10.8	77
231	Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 851-859.	10.2	331
232	Clinical, Neuropathological, and Biochemical Characterization of the Novel Tau Mutation P332S. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 741-749.	2.6	25
233	Contribution of Single Photon Emission Computed Tomography to the Differential Diagnosis of Dementia in a Memory Clinic. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 833-845.	2.6	17
234	Cerebrovascular Lesions in Patients with Frontotemporal Lobar Degeneration: A Neuropathological Study. <i>Neurodegenerative Diseases</i> , 2012, 9, 170-175.	1.4	19

#	ARTICLE	IF	CITATIONS
235	Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. <i>Molecular Psychiatry</i> , 2012, 17, 223-233.	7.9	179
236	Gesture comprehension, knowledge and production in Alzheimer's disease. <i>European Journal of Neurology</i> , 2012, 19, 1037-1044.	3.3	28
237	Detection of microbleeds in post-mortem brains of patients with frontotemporal lobar degeneration: a 7.0-Tesla magnetic resonance imaging study with neuropathological correlates. <i>European Journal of Neurology</i> , 2012, 19, 1355-1360.	3.3	34
238	De la maladie de Pick aux démences fronto-temporales. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 431-443.	0.0	0
239	Abstract P2-13-10: Prospective randomized and multicentric evaluation of cognition in menopausal breast cancer patients receiving adjuvant hormone therapy: a phase III study (Preliminary results). , 2012, , .		0
240	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. <i>Brain</i> , 2011, 134, 2456-2477.	7.6	3,913
241	Prevalence of small cerebral bleeds in patients with a neurodegenerative dementia: A neuropathological study. <i>Journal of the Neurological Sciences</i> , 2011, 300, 63-66.	0.6	72
242	Study of thyroid hormone receptor alpha gene polymorphisms on Alzheimer's disease. <i>Neurobiology of Aging</i> , 2011, 32, 624-630.	3.1	16
243	The impact of cerebral amyloid angiopathy on the occurrence of cerebrovascular lesions in demented patients with Alzheimer features: a neuropathological study. <i>European Journal of Neurology</i> , 2011, 18, 913-918.	3.3	54
244	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. <i>Nature Genetics</i> , 2011, 43, 429-435.	21.4	1,708
245	APOE and Alzheimer disease: a major gene with semi-dominant inheritance. <i>Molecular Psychiatry</i> , 2011, 16, 903-907.	7.9	529
246	Origin of Piezoelectricity in an Electrospun Poly(vinylidene fluoride-trifluoroethylene) Nanofiber Web-Based Nanogenerator and Nano-Pressure Sensor. <i>Macromolecular Rapid Communications</i> , 2011, 32, 831-837.	3.9	316
247	Early Onset Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 203-205.	1.3	58
248	Study of Estrogen Receptor-1 and Receptor-2 Gene Polymorphisms on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 431-439.	2.6	18
249	Comparison of 7.0-Tesla Magnetic Resonance Imaging of Cerebral Bleeds in Post-Mortem Brain Sections of Alzheimer Patients with Their Neuropathological Correlates. <i>Cerebrovascular Diseases</i> , 2011, 31, 511-517.	1.7	75
250	Implication of the Immune System in Alzheimer's Disease: Evidence from Genome-Wide Pathway Analysis. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1107-1118.	2.6	152
251	The CALHM1 P86L Polymorphism is a Genetic Modifier of Age at Onset in Alzheimer's Disease: a Meta-Analysis Study. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 247-255.	2.6	54
252	Systematic Analysis of Candidate Genes for Alzheimer's Disease in a French, Genome-Wide Association Study. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1181-1188.	2.6	63

#	ARTICLE	IF	CITATIONS
253	Biomarkers for the Early Stages of Clinical Development in Alzheimer's Disease. <i>Thérapie</i> , 2010, 65, 285-290.	1.0	1
254	CHMP2B mutations are rare in French families with frontotemporal lobar degeneration. <i>Journal of Neurology</i> , 2010, 257, 2032-2036.	3.6	21
255	Sleep disorders in aging and dementia. <i>Journal of Nutrition, Health and Aging</i> , 2010, 14, 212-217.	3.3	179
256	An analysis of communication in conversation in patients with dementia. <i>Neuropsychologia</i> , 2010, 48, 3884-3890.	1.6	94
257	Joint Effect of White Matter Lesions and Hippocampal Volumes on Severity of Cognitive Decline: The 3C-Dijon MRI Study. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 453-463.	2.6	97
258	Is the Urea Cycle Involved in Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 1013-1021.	2.6	68
259	Rapid categorization of faces and objects in a patient with impaired object recognition. <i>Neurocase</i> , 2010, 16, 157-168.	0.6	7
260	Prediction of pathology in primary progressive language and speech disorders. <i>Neurology</i> , 2010, 74, 42-49.	1.1	187
261	What are the causes of pre-existing dementia in patients with intracerebral haemorrhages?. <i>Brain</i> , 2010, 133, 3281-3289.	7.6	74
262	A study of the association between the ADAM12 and SH3PXD2A (SH3MD1) genes and Alzheimer's disease. <i>Neuroscience Letters</i> , 2010, 468, 1-2.	2.1	15
263	An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. <i>Experimental Neurology</i> , 2010, 223, 432-438.	4.1	10
264	Diabetes and cognitive impairment: how to evaluate the cognitive status?. <i>Diabetes and Metabolism</i> , 2010, 36, S100-S105.	2.9	26
265	Drugs With Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population. <i>Archives of Internal Medicine</i> , 2009, 169, 1317.	3.8	312
266	Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. <i>Neurology</i> , 2009, 73, 674-680.	1.1	214
267	Bilateral Temporal Glioma Presenting as a Paraneoplastic Limbic Encephalitis With Pure Cognitive Impairment. <i>Neurologist</i> , 2009, 15, 208-211.	0.7	13
268	Long-term outcome of acute and subacute myelopathies. <i>Journal of Neurology</i> , 2009, 256, 980-988.	3.6	52
269	Mild Alzheimer's disease: A «Position Paper». <i>Journal of Nutrition, Health and Aging</i> , 2009, 13, 503-519.	3.3	10
270	Evidence for induction of the ornithine transcarbamylase expression in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2009, 14, 106-116.	7.9	43

#	ARTICLE	IF	CITATIONS
271	Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease. <i>Molecular Psychiatry</i> , 2009, 14, 1004-1016.	7.9	167
272	Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. <i>Nature Genetics</i> , 2009, 41, 1094-1099.	21.4	2,155
273	Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 133-139.	1.9	72
274	Siderophile and chalcophile elemental constraints on the origin of the Jinchuan Ni-Cu-(PGE) sulfide deposit, NW China. <i>Geochimica Et Cosmochimica Acta</i> , 2009, 73, 404-424.	3.9	91
275	Is the ornithine transcarbamylase gene a genetic determinant of Alzheimer's disease?. <i>Neuroscience Letters</i> , 2009, 449, 76-80.	2.1	9
276	Graph wavelet applied to human brain connectivity. , 2009, , .		2
277	Relevance of the Evaluation Criteria Used in Clinical Trials for Alzheimer's Disease. <i>Therapie</i> , 2009, 64, 145-148.	1.0	5
278	CP measurement in quantum teleportation of neutral mesons. <i>European Physical Journal C</i> , 2008, 55, 477-482.	3.9	8
279	Evaluation of the Impact of Memantine Treatment Initiation on Psychotropics Use: A Study from the French National Health Care Database. <i>Neuroepidemiology</i> , 2008, 31, 193-200.	2.3	28
280	Association study of the GAB2 gene with the risk of developing Alzheimer's disease. <i>Neurobiology of Disease</i> , 2008, 30, 103-106.	4.4	34
281	Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease. <i>Neurobiology of Disease</i> , 2008, 31, 41-45.	4.4	66
282	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. <i>Expert Review of Proteomics</i> , 2008, 5, 207-224.	3.0	242
283	A Polymorphism in CALHM1 Influences Ca ²⁺ Homeostasis, A β Levels, and Alzheimer's Disease Risk. <i>Cell</i> , 2008, 133, 1149-1161.	28.9	310
284	Vascular Subcortical Hyperintensities Predict Conversion to Vascular and Mixed Dementia in MCI Patients. <i>Stroke</i> , 2008, 39, 2046-2051.	2.0	82
285	Cognitive Decline and Survival in Alzheimer's Disease according to Education Level. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 25, 74-80.	1.5	65
286	Primary and Secondary Care Consultations in Elderly Demented Individuals in France. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 407-415.	1.5	34
287	Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. <i>Brain</i> , 2008, 131, 772-784.	7.6	206
288	Risk profiles for mild cognitive impairment and progression to dementia are gender specific. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 979-984.	1.9	222

#	ARTICLE	IF	CITATIONS
289	Association study of the NEDD9 gene with the risk of developing Alzheimer's and Parkinson's disease. <i>Human Molecular Genetics</i> , 2008, 17, 2863-2867.	2.9	21
290	Tau as a biomarker of neurodegenerative diseases. <i>Biomarkers in Medicine</i> , 2008, 2, 363-384.	1.4	83
291	Phenotype variability in progranulin mutation carriers: a clinical, neuropsychological, imaging and genetic study. <i>Brain</i> , 2008, 131, 732-746.	7.6	331
292	Memantine Therapy for Alzheimer Disease in Real-world Practice. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 125-130.	1.3	29
293	Les DÃ©mences Frontotemporales. , 2008, , 123-135.		1
294	Amnesic syndrome of the medial temporal type identifies prodromal AD. <i>Neurology</i> , 2007, 69, 1859-1867.	1.1	425
295	Influence of cognitive impairment on the institutionalisation rate 3 years after a stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 56-59.	1.9	91
296	Prevalence of Subcortical Vascular Lesions and Association With Executive Function in Mild Cognitive Impairment Subtypes. <i>Stroke</i> , 2007, 38, 2595-2597.	2.0	70
297	Subcortical Hyperintensities Are Associated With Cognitive Decline in Patients With Mild Cognitive Impairment. <i>Stroke</i> , 2007, 38, 2924-2930.	2.0	145
298	Absence of Î²-Amyloid Deposits After Immunization in Alzheimer Disease With Lewy Body Dementia. <i>Archives of Neurology</i> , 2007, 64, 583.	4.5	67
299	Patients characteristics with cholinesterase inhibitor resistant hallucinations in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1415-1416.	1.9	3
300	Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 23, 401-405.	1.5	82
301	Central and Peripheral Agraphia in Alzheimer's Disease: From the Case of Auguste D. to a Cognitive Neuropsychology Approach. <i>Cortex</i> , 2007, 43, 935-951.	2.4	46
302	Declaration of San Antonio, Texas. <i>Neuroepidemiology</i> , 2007, 28, 191-192.	2.3	2
303	Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. <i>Lancet Neurology</i> , The, 2007, 6, 734-746.	10.2	3,755
304	Diabetes mellitus and dementia. <i>Diabetes and Metabolism</i> , 2006, 32, 403-414.	2.9	231
305	Different patterns of Mini Mental Status Examination responses in primary progressive aphasia and Alzheimer's disease. <i>European Journal of Neurology</i> , 2006, 13, 1124-1127.	3.3	10
306	Phenotype associated with APP duplication in five families. <i>Brain</i> , 2006, 129, 2966-2976.	7.6	230

#	ARTICLE	IF	CITATIONS
307	Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 278-288.	1.7	95
308	Influence of Dementia on Antithrombotic Therapy Prescribed before Stroke in Patients with Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2006, 21, 401-407.	1.7	4
309	Poststroke Dementia. <i>Cerebrovascular Diseases</i> , 2006, 22, 61-70.	1.7	91
310	Early epileptic seizures after stroke are associated with increased risk of new-onset dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 514-516.	1.9	48
311	Telling the difference between frontotemporal dementia and Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2005, 18, 628-632.	6.3	16
312	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2005, 65, 1863-1872.	1.1	4,604
313	Poststroke dementia. <i>Lancet Neurology</i> , The, 2005, 4, 752-759.	10.2	578
314	Prevalence of risk factors of prion-related disease according to the French circular 138 (DGS/DH/5C/DHOS/E2/2001/138) among patients referred for gastrointestinal endoscopy. <i>Gastroenterologie Clinique Et Biologique</i> , 2005, 29, 664-666.	0.9	0
315	Prestroke dementia in patients with atrial fibrillation. <i>Journal of Neurology</i> , 2005, 252, 1504-1509.	3.6	11
316	Disturbance of sensory filtering in dementia with Lewy bodies: comparison with Parkinson's disease dementia and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 106-108.	1.9	59
317	Natural history of primary progressive aphasia. <i>Neurology</i> , 2005, 65, 887-891.	1.1	108
318	Influence of pre-existing dementia on the risk of post-stroke epileptic seizures. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1649-1653.	1.9	63
319	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1624-1629.	1.9	101
320	Perception of Emotion on Faces in Frontotemporal Dementia and Alzheimer's Disease: A Longitudinal Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 19, 37-41.	1.5	98
321	Poststroke Dementia in the Elderly. <i>Drugs and Aging</i> , 2005, 22, 483-493.	2.7	27
322	Frontotemporal Dementia: A Randomised, Controlled Trial with Trazodone. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 355-359.	1.5	314
323	Depressive symptoms after stroke and relationship with dementia. <i>Neurology</i> , 2004, 62, 905-911.	1.1	129
324	Comparison of secondary vascular prevention in practice after cerebral ischemia and coronary heart disease. <i>Journal of Neurology</i> , 2004, 251, 529-536.	3.6	8

#	ARTICLE	IF	CITATIONS
325	Simulation of nonlinear interactions between waves and floating bodies through a finite-element-based numerical tank. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2004, 460, 2797-2817.	2.1	78
326	Natural History of Frontotemporal Dementia: Comparison with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2004, 17, 253-257.	1.5	86
327	Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 368, 290-292.	2.1	28
328	P1-048 Natural history of primary progressive aphasia. <i>Neurobiology of Aging</i> , 2004, 25, S108.	3.1	0
329	Editorial Comment "Not All Hypertensive Subjects Have Similar Risks for White Matter Lesions: Influence of Genetic Factors. <i>Stroke</i> , 2004, 35, 1061-1062.	2.0	8
330	Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease. <i>Acta Neuropathologica</i> , 2003, 106, 575-583.	7.7	38
331	Influence of prestroke dementia on early and delayed mortality in stroke patients. <i>Journal of Neurology</i> , 2003, 250, 10-16.	3.6	74
332	Laboratory investigations and treatment in frontotemporal dementia. <i>Annals of Neurology</i> , 2003, 54, S32-S35.	5.3	22
333	Association of 3'-UTR polymorphisms of the oxidised LDL receptor 1 (OLR1) gene with Alzheimer's disease. <i>Journal of Medical Genetics</i> , 2003, 40, 424-430.	3.2	37
334	Leukoaraiosis More Than Dementia Is a Predictor of Stroke Recurrence. <i>Stroke</i> , 2003, 34, 2935-2940.	2.0	80
335	Poststroke Dementia. <i>Archives of Neurology</i> , 2003, 60, 585.	4.5	94
336	The dynamic time course of semantic memory impairment in Alzheimer's disease: clues from hyperpriming and hypoprimering effects. <i>Brain</i> , 2002, 125, 2044-2057.	7.6	88
337	Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer's disease. <i>Neurology</i> , 2002, 59, 398-407.	1.1	162
338	Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. <i>Neurology</i> , 2002, 59, 59-66.	1.1	102
339	Mutation analysis and association studies of the ubiquitin carboxy-terminal hydrolase L1 gene in Huntington's disease. <i>Neuroscience Letters</i> , 2002, 328, 1-4.	2.1	85
340	Tau aggregation in the hippocampal formation: an ageing or a pathological process?. <i>Experimental Gerontology</i> , 2002, 37, 1291-1296.	2.8	88
341	Poststroke dementia. <i>Neurology</i> , 2001, 57, 1216-1222.	1.1	318
342	The nature of semantic memory deficits in Alzheimer's disease: New insights from hyperpriming effects. <i>Brain</i> , 2001, 124, 1522-1532.	7.6	114

#	ARTICLE	IF	CITATIONS
343	Poststroke dementia. , 2001, , 273-284.		3
344	Chapter 8 Dementia. Blue Books of Practical Neurology, 2001, 25, 147-172.	0.1	0
345	Is There a Typical Pattern of Brain SPECT Imaging in Alzheimer's Disease?. Dementia and Geriatric Cognitive Disorders, 2001, 12, 371-378.	1.5	21
346	Silent infarcts in stroke patients: patient characteristics and effect on 2-year outcome. Journal of Neurology, 2001, 248, 271-278.	3.6	29
347	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. Stroke, 2001, 32, 1318-1322.	2.0	1,506
348	Relevance of White Matter Changes to Pre- and Poststroke Dementia. Annals of the New York Academy of Sciences, 2000, 903, 466-469.	3.8	28
349	Alzheimer's disease and frontotemporal dementia are differentiated by discriminant analysis applied to 99mTc HmPAO SPECT data. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 661-663.	1.9	90
350	The transcriptional factor LBP-1c/CP2/LSF gene on chromosome 12 is a genetic determinant of Alzheimer's disease. Human Molecular Genetics, 2000, 9, 2275-2280.	2.9	75
351	A FE65 polymorphism associated with risk of developing sporadic late-onset Alzheimer's disease but not with A β 2 loading in brains. Neuroscience Letters, 2000, 293, 29-32.	2.1	31
352	The Clinical Picture of Frontotemporal Dementia: Diagnosis and Follow-Up. Dementia and Geriatric Cognitive Disorders, 1999, 10, 10-14.	1.5	103
353	Confusional State in Stroke. Stroke, 1999, 30, 773-779.	2.0	143
354	Neuropsychiatric afflictions of modern French Presidents: Marçchal Henriâ€Philippe PÃ©tain and Paul Deschanel. European Journal of Neurology, 1999, 6, 133-136.	3.3	10
355	Early diagnosis of dementia: neuropsychology. Journal of Neurology, 1999, 246, 6-15.	3.6	288
356	Association between coding variability in the LRP gene and the risk of late-onset Alzheimer's disease. Human Genetics, 1999, 104, 432-434.	3.8	53
357	Trazodone in the treatment of behaviour in frontotemporal dementia. Human Psychopharmacology, 1999, 14, 279-281.	1.5	23
358	Prevention of dementia: Syst-Eur trial. Lancet, The, 1999, 353, 236.	18.7	10
359	Perception of Emotion in Frontotemporal Dementia and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 1999, 13, 96-101.	1.3	178
360	Vascular Dementia: The Role of Cerebral Infarcts. Alzheimer Disease and Associated Disorders, 1999, 13, S38-S48.	1.3	30

#	ARTICLE	IF	CITATIONS
361	The Cognitive Syndrome of Vascular Dementia: Implications for Clinical Trials. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, S21-S29.	1.3	9
362	The Cognitive Syndrome of Vascular Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 1999, 13, S21-29.	1.3	36
363	The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. <i>Neurology</i> , 1999, 52, 1158-1158.	1.1	704
364	Tacrine efficacy in Lewy body dementia. <i>International Journal of Geriatric Psychiatry</i> , 1998, 13, 516-519.	2.7	37
365	Medial temporal lobe atrophy in stroke patients: relation to pre-existing dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 65, 641-647.	1.9	71
366	Creutzfeldt-Jakob disease. <i>Neurology</i> , 1998, 51, 962-967.	1.1	32
367	Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. <i>Human Molecular Genetics</i> , 1998, 7, 1511-1516.	2.9	127
368	White Matter Changes on CT and MRI: An Overview of Visual Rating Scales. <i>European Neurology</i> , 1998, 39, 80-89.	1.4	244
369	A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. <i>Human Molecular Genetics</i> , 1998, 7, 533-540.	2.9	170
370	Epidemiology of Vascular Dementia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998, 28, 134-150.	0.3	19
371	Frontotemporal Behavioral Scale. <i>Alzheimer Disease and Associated Disorders</i> , 1998, 12, 335-339.	1.3	109
372	Tolerance to tacrine, arterial hypotension and leuko-araiosis in Alzheimer's disease. <i>Age and Ageing</i> , 1998, 27, 654-654.	1.6	1
373	Explicit Memory in Frontotemporal Dementia: The Role of Medial Temporal Atrophy. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 99-102.	1.5	28
374	White Matter Changes and Poststroke Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 1998, 9, 25-29.	1.5	40
375	Non-Alzheimer degenerative dementias. <i>Current Opinion in Neurology</i> , 1998, 11, 417-427.	3.6	39
376	Lewy Body Influence on Tacrine Efficacy. <i>Advances in Behavioral Biology</i> , 1998, , 477-480.	0.2	0
377	Association between medial temporal lobe atrophy on CT and parietotemporal uptake decrease on SPECT in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 441-445.	1.9	10
378	The Use of SPECT in a Multidisciplinary Memory Clinic. <i>Dementia and Geriatric Cognitive Disorders</i> , 1997, 8, 85-91.	1.5	24

#	ARTICLE	IF	CITATIONS
379	No effect of the alpha 1-antichymotrypsin A allele in Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997, 63, 103-105.	1.9	13
380	Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging. <i>European Neurology</i> , 1997, 37, 95-99.	1.4	166
381	Frontotemporal Dementia: Its Rediscovery. <i>European Neurology</i> , 1997, 38, 1-6.	1.4	59
382	Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. <i>Neuroscience Letters</i> , 1997, 227, 68-70.	2.1	92
383	Why are stroke patients prone to develop dementia?. <i>Journal of Neurology</i> , 1997, 244, 135-142.	3.6	238
384	Medial temporal lobe atrophy in memory disorders. <i>Journal of Neurology</i> , 1997, 244, 175-181.	3.6	45
385	Preexisting Dementia in Stroke Patients. <i>Stroke</i> , 1997, 28, 2429-2436.	2.0	208
386	Generation Effect in Short-Term Verbal and Visuospatial Memory: Comparisons Between Dementia of Alzheimer Type and Dementia of Frontal Lobe Type. <i>Cortex</i> , 1996, 32, 347-356.	2.4	26
387	Convulsive effects of tacrine. <i>Lancet, The</i> , 1996, 347, 1339-1340.	13.7	23
388	Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. <i>European Neurology</i> , 1996, 36, 268-272.	1.4	383
389	Sundowning syndrome in demented patients without neuroleptic therapy. <i>Archives of Gerontology and Geriatrics</i> , 1996, 22, 49-54.	3.0	22
390	Segregation analysis of Alzheimer pedigrees: Rare mendelian dominant mutation(s) explain a minority of early-onset cases. <i>American Journal of Medical Genetics Part A</i> , 1996, 67, 9-12.	2.4	10
391	Dementia in stroke. <i>Neurology</i> , 1996, 47, 852-853.	1.1	12
392	Allelic association at the D14S43 locus in early onset Alzheimer's disease. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 91-93.	2.4	4
393	Characteristics of familial aggregation in early-onset Alzheimer's disease: Evidence of subgroups. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 221-227.	2.4	7
394	Evidence for apolipoprotein E ϵ 4 association in early-onset Alzheimer's patients with late-onset relatives. <i>American Journal of Medical Genetics Part A</i> , 1995, 60, 550-553.	2.4	28
395	Personality traits and frontal lobe dementia. <i>International Journal of Geriatric Psychiatry</i> , 1995, 10, 1047-1049.	2.7	20
396	Verbal fluency in dementia of frontal lobe type and dementia of Alzheimer type.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 81-84.	1.9	131

#	ARTICLE	IF	CITATIONS
397	Calculation and number processing in mild Alzheimer's disease. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1995, 17, 634-639.	1.3	41
398	Follow-Up of Patients with History of Cervical Artery Dissection. <i>Cerebrovascular Diseases</i> , 1995, 5, 43-49.	1.7	148
399	Mutations of the <i>presenilin 1</i> gene in families with early-onset Alzheimer's disease. <i>Human Molecular Genetics</i> , 1995, 4, 2373-2377.	2.9	268
400	Methylenetetrahydrofolate reductase deficiency revealed by a neuropathy in a psychotic adult.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 765-766.	1.9	44
401	Affective disorders related to spect patterns in alzheimer's disease: A study of emotionalism. <i>International Journal of Geriatric Psychiatry</i> , 1994, 9, 327-329.	2.7	9
402	Motor memory and the preselection effect in Huntington's and Parkinson's disease. <i>Neuropsychologia</i> , 1994, 32, 951-968.	1.6	11
403	Determination of medial temporal lobe atrophy In early Alzheimer's disease with computed tomography. <i>Lancet, The</i> , 1994, 343, 861-862.	13.7	17
404	SPECT Data in a Case of Secondary Capgras Delusion. <i>Psychopathology</i> , 1994, 27, 211-214.	1.5	21
405	Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1993, 56, 112-113.	1.9	12
406	Meningitis Caused BySalmonella Enteritidis in an Adult. <i>Acta Clinica Belgica</i> , 1992, 47, 215-216.	1.2	5
407	Clinical and Imaging Characteristics of Vascular Dementia in a Memory Clinic. , 0, , 219-228.		0
408	Poststroke dementia. , 0, , 245-254.		0
409	Treatment of patients with post-stroke dementia. , 0, , 423-431.		0